Warning against botulinum toxin slimming injections in Turkey

Patients have been warned not to fly to Turkey to receive botulinum neurotoxin (BoNT) injections in their stomach for weight loss following almost 70 reported botulism cases. According to the European Centre for Disease Prevention and Control (ECDC), 67 patients have been diagnosed with the life-threatening condition after receiving BoNT injections to relax the stomach wall and reduce appetite, with some requiring admittance into Intensive Care Units (ICU). Turkish investigations have found that a legitimate product was used during these procedures, but it was not licensed for this procedure. The involved facilities have since been shut down. The ECDC is now advising patients not to seek this treatment in Turkey, as it says the procedure carries a “significant risk of developing botulism.”

Digital Galderma to host webinar with Aesthetics

Pharmaceutical company Galderma will be hosting a webinar in partnership with the Aesthetics journal this month. The webinar will focus on clinical efficacy and safety of Abobotulinum toxin type A in powder and ready-to-use forms to help practitioners understand the use of both products in their practice. The ‘Innovation Through Science: The Clinical Evidence of Galderma’s Neuromodulator Portfolio’ webinar will be led by aesthetic practitioners Dr Munir Somji and Dr Lara Watson. Rene Wipperich, general manager at Galderma, commented, “We are very proud to have launched our new neuromodulator in March. Galderma will continue its commitment to bring new scientific solutions to our customers and drive innovation in the future.” The webinar will be taking place on April 25 at 7:30pm GMT. Innovation